Foghorn Therapeutics (FHTX) Amortizatization of Intangibles (2020 - 2026)
Foghorn Therapeutics (FHTX) recorded quarterly Amortizatization of Intangibles of $388000.0 in Q1 2026, up 26.8% quarter-over-quarter from $306000.0 in Q4 2025, and down 52.57% on a YoY basis from $818000.0 in Q1 2025.
Foghorn Therapeutics (FHTX) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' Amortizatization of Intangibles history runs 7 years deep, the most recent figure standing at $388000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 52.57% year-over-year to $388000.0; the TTM figure through Mar 2026 stood at $1.5 million (down 69.33% YoY), while the FY2025 annual figure was $1.9 million, down 58.25% from the prior year.
- Amortizatization of Intangibles was $388000.0 for Q1 2026 at Foghorn Therapeutics, up from $306000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.8 million in Q3 2024 to a low of -$38000.0 in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $639588.2 across 5 years, with a median of $554000.0 in 2024.
- Biggest YoY gain for Amortizatization of Intangibles was 6540.0% in 2022; the steepest drop was 392.31% in 2022.
- A 5-year view of Amortizatization of Intangibles shows it stood at $574000.0 in 2022, then slipped by 13.76% to $495000.0 in 2023, then surged by 216.97% to $1.6 million in 2024, then sank by 80.5% to $306000.0 in 2025, then increased by 26.8% to $388000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $388000.0 (Q1 2026), $306000.0 (Q4 2025), and $356000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Foghorn Therapeutics | 282.33 Mn | 193.42 Mn | - | 388,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 388,000.00 |
| Mar 31, 2026 | 388,000.00 |
| Dec 31, 2025 | 306,000.00 |
| Dec 31, 2025 | 306,000.00 |
| Sep 30, 2025 | 356,000.00 |
| Sep 30, 2025 | 356,000.00 |
| Jun 30, 2025 | 446,000.00 |
| Jun 30, 2025 | 446,000.00 |
| Mar 31, 2025 | 818,000.00 |
| Mar 31, 2025 | 818,000.00 |
| Dec 31, 2024 | 1.57 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Sep 30, 2024 | 1.79 Mn |
| Sep 30, 2024 | 1.79 Mn |
| Jun 30, 2024 | 705,000.00 |
| Jun 30, 2024 | 705,000.00 |
| Mar 31, 2024 | 554,000.00 |
| Mar 31, 2024 | 554,000.00 |
| Dec 31, 2023 | 495,000.00 |
| Dec 31, 2023 | 495,000.00 |